Glucose Transporter Type I Deficiency and Other Glucose Flux Disorders

Juan M. Pascual, Dong Wang, Darryl C. De Vivo

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

The majority of patients with glucose transporter type I deficiency (G1D) are haploinsufficient in SLC2A1, the gene that encodes the glucose transporter isoforms present both in the endothelial cells of the blood-brain barrier and in astrocytes. G1D is expected, on biochemical principles, to result in decreased blood to brain and intracerebral glucose flux and, in mice, this is associated with diminished cerebral acetyl-coenzyme A contents. Thus, G1D probably stems from depletion (or perhaps from repletion) of energetic precursors centrally situated with respect to cerebral metabolism. Paradoxically, G1D is not associated with global neural hypoexcitability as a result of diminished glucose influx, but with focal hyperexcitability: Spike-wave epilepsy and paroxysmal dyskinesia constitute the best-defined G1D syndromes. Many patients also exhibit dystonia, ataxia and dysarthria, either in isolation or in conjunction with other nonmotor manifestations such as intellectual disability and microcephaly. A ketogenic diet has been effective in controlling seizures but has had little measurable effect on the associated cognitive impairment and behavioral disturbances. As the number of cases increases worldwide, it becomes more important to expand our understanding of the clinical phenotypes and to explore alternative treatment strategies designed to mitigate the impact of impaired brain glucose influx during early neurologic development.

Original languageEnglish (US)
Title of host publicationRosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease: Fifth Edition
PublisherElsevier Inc.
Pages649-662
Number of pages14
ISBN (Print)9780124105294, 9780124105492
DOIs
StatePublished - Nov 13 2014

Fingerprint

Facilitative Glucose Transport Proteins
Glucose
Ketogenic Diet
Chorea
Dysarthria
Microcephaly
Acetyl Coenzyme A
Dystonia
Brain
Ataxia
Blood-Brain Barrier
Astrocytes
Intellectual Disability
Nervous System
Epilepsy
Protein Isoforms
Seizures
Endothelial Cells
Phenotype
Genes

Keywords

  • Absence
  • Astrocyte
  • Ataxia
  • Blood-brain barrier
  • Chorea
  • Dyskinesia
  • Dystonia
  • Epilepsy
  • G1D
  • GABA
  • Glut1
  • Glut1 deficiency
  • Glutamate
  • Hemolysis
  • Ketogenic diet
  • Spasticity
  • Spike-wave
  • Synapse
  • Thalamocortical

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pascual, J. M., Wang, D., & De Vivo, D. C. (2014). Glucose Transporter Type I Deficiency and Other Glucose Flux Disorders. In Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease: Fifth Edition (pp. 649-662). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-410529-4.00058-9

Glucose Transporter Type I Deficiency and Other Glucose Flux Disorders. / Pascual, Juan M.; Wang, Dong; De Vivo, Darryl C.

Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease: Fifth Edition. Elsevier Inc., 2014. p. 649-662.

Research output: Chapter in Book/Report/Conference proceedingChapter

Pascual, JM, Wang, D & De Vivo, DC 2014, Glucose Transporter Type I Deficiency and Other Glucose Flux Disorders. in Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease: Fifth Edition. Elsevier Inc., pp. 649-662. https://doi.org/10.1016/B978-0-12-410529-4.00058-9
Pascual JM, Wang D, De Vivo DC. Glucose Transporter Type I Deficiency and Other Glucose Flux Disorders. In Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease: Fifth Edition. Elsevier Inc. 2014. p. 649-662 https://doi.org/10.1016/B978-0-12-410529-4.00058-9
Pascual, Juan M. ; Wang, Dong ; De Vivo, Darryl C. / Glucose Transporter Type I Deficiency and Other Glucose Flux Disorders. Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease: Fifth Edition. Elsevier Inc., 2014. pp. 649-662
@inbook{869f2ee2e4a64376996e9902aacee5a9,
title = "Glucose Transporter Type I Deficiency and Other Glucose Flux Disorders",
abstract = "The majority of patients with glucose transporter type I deficiency (G1D) are haploinsufficient in SLC2A1, the gene that encodes the glucose transporter isoforms present both in the endothelial cells of the blood-brain barrier and in astrocytes. G1D is expected, on biochemical principles, to result in decreased blood to brain and intracerebral glucose flux and, in mice, this is associated with diminished cerebral acetyl-coenzyme A contents. Thus, G1D probably stems from depletion (or perhaps from repletion) of energetic precursors centrally situated with respect to cerebral metabolism. Paradoxically, G1D is not associated with global neural hypoexcitability as a result of diminished glucose influx, but with focal hyperexcitability: Spike-wave epilepsy and paroxysmal dyskinesia constitute the best-defined G1D syndromes. Many patients also exhibit dystonia, ataxia and dysarthria, either in isolation or in conjunction with other nonmotor manifestations such as intellectual disability and microcephaly. A ketogenic diet has been effective in controlling seizures but has had little measurable effect on the associated cognitive impairment and behavioral disturbances. As the number of cases increases worldwide, it becomes more important to expand our understanding of the clinical phenotypes and to explore alternative treatment strategies designed to mitigate the impact of impaired brain glucose influx during early neurologic development.",
keywords = "Absence, Astrocyte, Ataxia, Blood-brain barrier, Chorea, Dyskinesia, Dystonia, Epilepsy, G1D, GABA, Glut1, Glut1 deficiency, Glutamate, Hemolysis, Ketogenic diet, Spasticity, Spike-wave, Synapse, Thalamocortical",
author = "Pascual, {Juan M.} and Dong Wang and {De Vivo}, {Darryl C.}",
year = "2014",
month = "11",
day = "13",
doi = "10.1016/B978-0-12-410529-4.00058-9",
language = "English (US)",
isbn = "9780124105294",
pages = "649--662",
booktitle = "Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease: Fifth Edition",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Glucose Transporter Type I Deficiency and Other Glucose Flux Disorders

AU - Pascual, Juan M.

AU - Wang, Dong

AU - De Vivo, Darryl C.

PY - 2014/11/13

Y1 - 2014/11/13

N2 - The majority of patients with glucose transporter type I deficiency (G1D) are haploinsufficient in SLC2A1, the gene that encodes the glucose transporter isoforms present both in the endothelial cells of the blood-brain barrier and in astrocytes. G1D is expected, on biochemical principles, to result in decreased blood to brain and intracerebral glucose flux and, in mice, this is associated with diminished cerebral acetyl-coenzyme A contents. Thus, G1D probably stems from depletion (or perhaps from repletion) of energetic precursors centrally situated with respect to cerebral metabolism. Paradoxically, G1D is not associated with global neural hypoexcitability as a result of diminished glucose influx, but with focal hyperexcitability: Spike-wave epilepsy and paroxysmal dyskinesia constitute the best-defined G1D syndromes. Many patients also exhibit dystonia, ataxia and dysarthria, either in isolation or in conjunction with other nonmotor manifestations such as intellectual disability and microcephaly. A ketogenic diet has been effective in controlling seizures but has had little measurable effect on the associated cognitive impairment and behavioral disturbances. As the number of cases increases worldwide, it becomes more important to expand our understanding of the clinical phenotypes and to explore alternative treatment strategies designed to mitigate the impact of impaired brain glucose influx during early neurologic development.

AB - The majority of patients with glucose transporter type I deficiency (G1D) are haploinsufficient in SLC2A1, the gene that encodes the glucose transporter isoforms present both in the endothelial cells of the blood-brain barrier and in astrocytes. G1D is expected, on biochemical principles, to result in decreased blood to brain and intracerebral glucose flux and, in mice, this is associated with diminished cerebral acetyl-coenzyme A contents. Thus, G1D probably stems from depletion (or perhaps from repletion) of energetic precursors centrally situated with respect to cerebral metabolism. Paradoxically, G1D is not associated with global neural hypoexcitability as a result of diminished glucose influx, but with focal hyperexcitability: Spike-wave epilepsy and paroxysmal dyskinesia constitute the best-defined G1D syndromes. Many patients also exhibit dystonia, ataxia and dysarthria, either in isolation or in conjunction with other nonmotor manifestations such as intellectual disability and microcephaly. A ketogenic diet has been effective in controlling seizures but has had little measurable effect on the associated cognitive impairment and behavioral disturbances. As the number of cases increases worldwide, it becomes more important to expand our understanding of the clinical phenotypes and to explore alternative treatment strategies designed to mitigate the impact of impaired brain glucose influx during early neurologic development.

KW - Absence

KW - Astrocyte

KW - Ataxia

KW - Blood-brain barrier

KW - Chorea

KW - Dyskinesia

KW - Dystonia

KW - Epilepsy

KW - G1D

KW - GABA

KW - Glut1

KW - Glut1 deficiency

KW - Glutamate

KW - Hemolysis

KW - Ketogenic diet

KW - Spasticity

KW - Spike-wave

KW - Synapse

KW - Thalamocortical

UR - http://www.scopus.com/inward/record.url?scp=84943339531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943339531&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-410529-4.00058-9

DO - 10.1016/B978-0-12-410529-4.00058-9

M3 - Chapter

SN - 9780124105294

SN - 9780124105492

SP - 649

EP - 662

BT - Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease: Fifth Edition

PB - Elsevier Inc.

ER -